AEAhmed El-Bardissy

Ahmed El-Bardissy

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ahmed El-Bardissy has a total of 82 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Severe resistant hypercalcemia complicating rhabdomyolysis: a case report and review of the literature

    by Ali Ibrahim Ali Rahil, Ahmed El-Bardissy, Ahmed Elmudathir Osman, Munir Abu Ageila, Nada H. Soliman, Razan Rahil

    Rhabdomyolysis is a clinical syndrome that follows destruction of skeletal muscles releasing a number of toxic substances and electrolytes causing hyperkalemia, hyperphosphatemia, and hypocalcemia. However, hypercalcemia may arise during the recovery phase of rhabdomyolysis and can be life-threatening. A 31-year-old previously healthy Egyptian man was admitted to the surgical unit in the teaching hospital for 4-day history of peri-anal pain, fever, vomiting, and diarrhea. He was found to have peri-anal abscess for which he underwent multiple sessions of surgical debridement. His kidney function deteriorated rapidly in the first few days with hyperkalemia resistant to medical therapy and oliguria requiring hemodialysis. His serum calcium during the period of acute kidney injury was low as expected with high serum phosphorus and elevated myoglobin and creatine kinase (CK) indicating rhabdomyolysis. However, he developed severe hypercalcemia during recovery phase peaking at 5.62 mmol/L (23 mg/dl). Plasma levels of PTH hormone, 25-hydroxy-vitamin D, and 1,25 hydroxy-vitamin D were low whilePTH-related peptide (PTHrP) was normal . Twenty four-hour urinary calcium level was high. Serum PTH-related peptide (PTHrP) was normal 0.7 pmol/L. Workup for hypercalcemia was unrevealing. Rhabdomyolysis was suggested as the cause of hypercalcemia. Massive degree of hypercalcemia can be the result of rhabdomyolysis and may be persistent and resistant to the conventional treatment of hypercalcemia. Although hypocalcemia is the immediate sequelae of rhabdomyolysis, marked hypercalcemia can follow the recovery phase of AKI due to rhabdomyolysis as a result of release of calcium that was sequestered in the damaged muscles. However, normocalcemia ultimately ensues. Clinicians should anticipate rebound hypercalcemia in rhabdomyolysis recovery, and resistant cases may require advanced therapy.

  • Open Access

    Derivation and Validation of a Genotype- Guided Warfarin Dosing Model in a Mixed Arab Population

    by Amr M. Fahmi, Ahmed El Bardissy, Mohamed Omar Saad, Islam Eljilany, Loulia Bader, Hazem Elewa

    Background: Previous studies demonstrated the superiority of a genotype-guided warfarin dosing (GWD) method for warfarin initiation. International GWD models such as Gage et al model were validated in diverse populations but Arab patients were not well represented in these studies. Objective: To derive and validate a GWD model in an Arab population and compare the outcomes to Gage et al model. Methods: In this cross-sectional study, DNA was collected through saliva kits from a cohort of recruited Arab patients on warfarin . Clinical factors and demographics were recorded and genotyping for VKORC1 (−1639G > A) , CYP2C9*2 , CYP2C9*3 and CYP4F2*3 was performed. Subjects were randomly divided to derivation and validation cohorts. Simple and Multiple linear regression analyses were used to identify factors associated with warfarin dose and derive a warfarin dosing model. The warfarin dose was also calculated using Gage et al model. Accuracy of the 2 models were compared through the mean absolute error (MAE) and percentage of predicted warfarin doses within 20% of the actual warfarin dose Results: The Arab cohort included 405 patients. In the derivation cohort (n = 270), multiple regression analysis showed a dosing model consisting of VKORC1 (−1639G > A) , CYP2C9*2 & CYP2C9*3 genotypes, along with other clinical factors (R 2 = 51.6%) (P < 0.05). When compared to Gage et al model, the Arab model had a significantly lower MAE of weekly warfarin dose (9.3 ± 7.6 mg/week vs 12.4 ± 10.4 mg/week, p = 0.03) Conclusion: A model derived and validated in an Arab population had better prediction accuracy compared to an internationally validated one.

  • Open Access

    Direct oral anticoagulants versus warfarin for venous thromboembolism prophylaxis in nephrotic syndrome patients: a retrospective study

    by Ahmed El-Bardissy, Mohamed Nabil Elshafei, Hebatullah Abdelgawad, Rana Mekkawi, Asma Eltahir, AbdulMoqeeth Mohammed, Ashour Am, Hazem Elewa

    Nephrotic syndrome (NS) is associated with an increased risk of venous thromboembolism (VTE). Anticoagulants are widely used in the prevention of VTE in NS patients. The use of direct oral anticoagulants (DOACs) has not been studied intensively in NS patients. The aim of this study is to determine the efficacy and safety of DOACs compared to warfarin for prophylactic anticoagulation in patients with nephrotic syndrome. Retrospective analysis conducted in a tertiary hospital-based ambulatory anticoagulation clinic between 01/07/2016 and 29/11/2021. We aimed to evaluate the incidence of VTE, major bleeding, and non-major bleeding in both the DOACs and warfarin groups. Fifty-seven patients were recruited, 31 patients were prescribed warfarin (54.4%), and 26 were on DOAC (45.6%). Two patients in the DOAC group developed VTE, while no subjects in the warfarin group developed VTE, however, the difference was not statistically significance (p = 0.2). Nine out of 31 patients in the warfarin group developed non-major bleeding compared to three patients in the DOAC group (p = 0.02). One patient developed major bleeding in each group DOAC group 1 (15.4%), warfarin 1 (12.9%) (p = 1.00). There was no statistically significant difference in major bleeding between DOAC and warfarin groups (p = 1.00). In patients with NS, preliminary evidence suggests that DOACs have comparable efficacy as compared to warfarin when used as prophylaxis. Additionally, DOACs result in lower incidences of non-major bleeding. However, further studies are indicated to confirm the superiority of DOACs over warfarin.


  • Open Access

    Clinical versus fixed warfarin dosing and the impact on quality of anticoagulation (The ClinFix trial)

    by Amr M. Fahmi, Ahmed El Bardissy, Mohamed Omar Saad, Mohamed Nabil Elshafei, Loulia Bader, Ahmed Mahfouz, Mohamed Kasem, Osama Abdelsamad, Abdelnasser Elzouki, Christina L. Aquilante, et al.

    Different dosing strategies exist to initiate warfarin, most commonly fixed warfarin dosing (FWD), clinical warfarin dosing (CWD), and genetic‐guided warfarin dosing (GWD). Landmark trials have shown GWD to be superior when compared to FWD in the EU‐PACT trial or CWD in the GIFT trial. COAG trial did not show differences between GWD and CWD. We aim to compare the anticoagulation quality outcomes of CWD and FWD. This is a prospective cohort study with a retrospective comparator. Recruited subjects in the CWD (prospective) arm were initiated on warfarin according to the clinical dosing component of the algorithm published in www.warfarindosing.org. The primary efficacy outcome was the percentage time in the therapeutic range (PTTR) from day 3 to 6 till day 28 to 35. The study enrolled 122 and 123 patients in the CWD and FWD, respectively. The PTTR did not differ statistically between CWD and FWD (62.2 ± 26.2% vs. 58 ± 25.4%, p = 0.2). There was also no difference between both arms in the percentage of visits with extreme subtherapeutic international normalized ratio (INR) (4; 7.7 ± 14.7% vs. 7.5 ± 12.4%, p = 0.92). We conclude that CWD did not improve the anticoagulation quality parameters compared to the FWD method.


  • Open Access

    Comparative Effectiveness and Safety of Direct Oral Anticoagulants in Low Body Weight Patients with Atrial Fibrillation: A Systematic Review and Meta-analysis

    by Mohamed Nabil Elshafei, Muhammad Salem, Ahmed El-Bardissy, Mohamed S. Abdelmoneim, Ahmed Khalil, Sherine Elhadad, Mutasem Al Mistarihi, Mohammed Danjuma

    Introduction: Direct oral anticoagulant (DOAC) agents are established as the anticoagulation strategy of choice for a variety of clinical risks. Despite this, uncertainty still exists with regard to their efficacy and safety for the prevention of stroke and systemic embolism in some patient populations; most notably those with low body weight (LBW) (2). Currently, there is a paucity of trial and non-trial data to support a prescriptive recommendation for their use in these patient cohorts. We have carried out a pooled systematic review of the most up to date published data of patients stabilized on various DOAC analogs with the view to ascertaining the exact matrices of their efficacy and safety in these cohorts of patients. Methods: We initially carried out a comprehensive search of databases from inception to June 2023 for eligible studies exploring the efficacy and safety of various analogs of direct oral anticoagulants in patients with atrial fibrillation who had low body weight. Databases accessed include PubMed, EMBASE, the Science Citation Index, the Cochrane Database of Systematic Reviews, and the Database of Abstracts of Reviews of Effectiveness. We carried out a weighted comparison of derived pooled odd ratios (with their corresponding confidence intervals) of mortality outcomes between various DOACs using the random effects model. Results: Thirteen studies (n = 165,205 patients) were included in our meta-analysis. DOAC analogs were associated with increased stroke-related events, composite outcome, and mortality in low body weight patients compared to non-low body weight patients (odds ratio [OR] 1.50, 95% confidence interval [CI] 1.17–1.92), (OR 1.55, 95% CI 1.29–1.86), (OR 2.92, 95% CI 1.87–4.58), respectively. There was no significant difference in the safety outcome (major bleeding events) between the DOAC analogs (OR 1.19, 95% CI 0.93–1.52). Discussion: In this meta-analytical review comprising both real-world and randomized controlled studies, the use of DOAC analogs in low body weight patients (body weight of 2) with atrial fibrillation was associated with increased risks of stroke-related events, composite outcomes, and mortality compared to non-low body weight cohorts patients. At the same time, there was no significant difference in terms of major bleeding events. This finding has provided the first resolution of pervading uncertainty surrounding the use of DOAC analogs in these patient cohorts and suggests the need for follow-up confirmatory systematic studies in this group of patients.


  • Open Access

    Warfarin‐Rifampin‐Gene (WARIF‐G) Interaction: A Retrospective, Genetic, Case–Control Study

    by Muhammad Salem, Ahmed El‐Bardissy, Mohamed Nabil Elshafei, Ahmed Khalil, Hesham Mahmoud, Amr Mohamed Fahmi, Mohamed Kasem, Loulia Bader, Mohamed Sherbash, Mostafa Ibrahim Elawady, et al.

    Warfarin is extensively metabolized by cytochrome P450 2C9 (CYP2C9). Concomitant use with the potent CYP2C9 inducer, rifampin, requires close monitoring and dosage adjustments. Although, in theory, warfarin dose increase should overcome this interaction, most reported cases over the last 50 years have not responded even to high warfarin doses, but some have responded to modest doses. To investigate the genetic polymorphisms' impact on this unexplained interpatient variability, we performed genotyping of CYP2C9, VKORC1, and CYP4F2 for warfarin and rifampin concomitant receivers from 2016 to 2022 at Hamad Medical Corporation, Doha, Qatar. We identified and included 36 patients: 22 responders and 14 nonresponders. Warfarin‐responders were significantly more likely to have one or more warfarin‐sensitizing CYP2C9/VKORC1 alleles than nonresponders (odds ratio = 23.2, 95% confidence interval = 3.2–195.6; P = 0.0001). The mean genetic‐based pre‐interaction calculated dose was significantly lower for responders than for nonresponders (P < 0.001); and was negatively correlated with warfarin sensitivity index (WSI) (r = −0.58; P = 0.0002). The median percentage time in therapeutic range and mean WSI were significantly higher in the warfarin‐sensitizing CYP2C9/VKORC1 alleles carriers than noncarriers (P = 0.017 and 0.0004, respectively). Whereas the warfarin‐sensitizing CYP2C9/VKORC1 genotypes were associated with modest on‐rifampin warfarin dose requirements, the noncarriers would have required more than double these doses to respond. Warfarin‐sensitizing CYP2C9/VKORC1 genotypes and low genetic‐based warfarin calculated doses were associated with higher warfarin sensitivity and better anticoagulation quality in patients receiving rifampin concomitantly.


  • Open Access

    Genetic Polymorphism Effect on Warfarin–Rifampin Interaction: A Case Report and Review of Literature

    by Muhammad Salem, Islam Eljilany, Ahmed El-Bardissy, Hazem Elewa

    Warfarin–rifampin interaction has been reported since the 1970s. Due to rifampin’s strong induction of CYP2C9, most cases could not attain the target international normalized ratio (INR) despite warfarin dose escalation. Genetic polymorphisms determine up to 50% of warfarin dose variability. A 38-year-old woman was started on warfarin and rifampin for cerebral venous sinus thrombosis and pulmonary tuberculosis. Over six weeks, the daily warfarin dose was increased from 3 to 10 mg to attain three consecutive in-clinic therapeutic INRs. She completed three complications-free months of warfarin treatment with time in therapeutic range (TTR) of 46%. We performed retrospective genetic testing to determine the patient’s CYP2C9, CYP4F2, and VKORC1 genotypes and whether they had affected the interaction outcome. The analysis revealed that the subject carries CYP2C9*3*3 and VKORC1-1639 (GA) mutations, classifying her as a slow metabolizer and, hence, highly warfarin-sensitive. This was reflected on how the case responded to a relatively lower dose than previously reported cases that did not achieve the target on warfarin daily doses up to 35 mg. This is the first report addressing the genotype effect on this interaction. Patients with genetic variants requiring low warfarin doses are more likely to respond at a feasible dose while on rifampin. Future studies to evaluate warfarin–rifampin-gene interaction are warranted.


  • Open Access

    The efficacy of colchicine in the management of coronavirus disease 2019

    by Mohamed Nabil Elshafei, Ahmed Msc Khalil, Ahmed El-Bardissy, Mohammed Mbbs Danjuma, Mohamed Badie Ahmed, Mouhand F.H. Md Mohamed

    Background: Severe acute respiratory syndrome coronavirus 2 (SARS-COV2) infection is a recently emerged viral infection causing predominantly mild upper respiratory symptoms. However, in some instances, it might result in acute respiratory distress syndrome (ARDS) that poses a significant mortality risk. ARDS is postulated to be mediated by a surge of pro-inflammatory cytokines and chemokines, leading to a dysregulated hyper inflammatory response. Colchicine being an anti-inflammatory agent, might mitigate this dysregulated response. Thus, in the absence of therapeutic options available to manage coronavirus disease 2019 (COVID-19), it is imperative to ascertain the effect of colchicine on improving outcomes in COVID-19 patients. Method: We will perform a systematic review including a search of the following databases: PubMed, EMBASE, MEDLINE, Clinicaltrials.gov, Cochrane library, and google scholar since inception. We will include randomized controlled trials exploring the effect of colchicine on the efficacy and safety outcomes of COVID-19 patients. Subsequently, we will perform a meta-analysis utilizing the random-effects to ascertain the effect of colchicine on reducing COVID-19 related mortality (primary endpoint) and other efficacy and safety outcomes. Results: Our review results are anticipated in early 2021 (based on the completion of several ongoing randomized controlled trial). Our review results will be published in a peer-reviewed journal. Conclusion: This systematic review and meta-analysis, is exploring the effect of colchicine on the efficacy and safety outcomes of COVID-19 patients. If colchicine proved to be effective, it would be a significant milestone in the management of COVID-19, a disease with limited available therapeutic options. PROSPERO registration number: CRD42020191086


  • Open Access

    Prevalence of Venous Thromboembolism in Critically-ill COVID-19 Patients: Systematic Review and Meta-analysis

    by Mouhand F.H. Mohamed, Shaikha D. Al-Shokri, Khaled M. Shunnar, Sara F. Mohamed, Mostafa S. Najim, Shahd I. Ibrahim, Hazem Elewa, Khalid M. Dousa, Lina O. Abdalla, Ahmed El-Bardissy, et al.

    Background: Recent studies revealed a high prevalence of venous thromboembolism (VTE) events in coronavirus disease 2019 (COVID-19) patients, especially in those who are critically ill. Available studies report varying prevalence rates. Hence, the exact prevalence remains uncertain. Moreover, there is an ongoing debate regarding the appropriate dosage of thromboprophylaxis. Methods: We performed a systematic review and proportion meta-analysis following PRISMA guidelines. We searched PubMed and EMBASE for studies exploring the prevalence of VTE in critically ill COVID-19 patients till 22/07/2020. We pooled the proportion of VTE. Additionally, in a subgroup analysis, we pooled VTE events detected by systematic screening. Finally, we compared the odds of VTE in patients on prophylactic compared to therapeutic anticoagulation. Results: The review comprised of 24 studies and over 2500 patients. The pooled proportion of VTE prevalence was 0.31 (95% CI 0.24, 0.39 I 2 94%), of VTE utilizing systematic screening was 0.48 (95% CI 0.33, 0.63 I 2 91%), of deep-venous-thrombosis was 0.23 (95% CI 0.14, 0.32 I 2 96%), of pulmonary embolism was 0.14 (95% CI 0.09, 0.20 I 2 90%). In a subgroup of studies, utilizing systematic screening, VTE risk increased significantly with prophylactic, compared to therapeutic anticoagulation (OR 5.45; 95% CI 1.90, 15.57 I 2 0%). Discussion: Our review revealed a high prevalence of VTE in critically ill COVID-19 patients. Almost 50% of patients had VTE detected by systematic screening. Higher thromboprophylaxis dosages seem to reduce VTE burden in this patient’s cohort compared to standard prophylactic anticoagulation; ongoing randomized controlled trials will further confirm this.

  • Open Access

    Comparative effectiveness and safety of direct oral anticoagulants compared to warfarin in morbidly obese patients with acute venous thromboembolism: systematic review and a meta-analysis

    by Mohamed Nabil Elshafei, Mouhand F. H. Mohamed, Ahmed El-Bardissy, Mohamed Badie Ahmed, Ibtihal Abdallah, Hazem Elewa, Mohammed Danjuma

    Direct oral anticoagulant (DOAC) agents are becoming the anticoagulation strategy of choice. However, their use in the treatment of acute venous thromboembolism (VTE) in morbidly obese patients (bodyweight of > 120 kg or BMI > 40 kg/m2) guarded. This is due to the scarce data supporting their use in this population. As a result, the International Society on Thrombosis and Haemostasis recommended against their use in this cohort of patients. New data emerged supporting the use of DOACs in these patients. Hence, we aimed to systematically review the literature exploring the efficacy and safety of these agents compared to warfarin in VTE treatment in morbidly obese patients. A systematic review of PubMed and EMBASE since inception until 01/04/2020. Subsequently, a non-inferiority (NI of 1.75) meta-analysis utilizing the random-effects model. Five observational studies (6585 patients) were included in our meta-analysis. DOAC analogs were non-inferior compared to warfarin in reducing the primary efficacy outcome of VTE recurrence (OR 1.07, 95% CI 0.93–1.23) and the primary safety outcome (major bleeding events) (OR 0.80, 95% CI 0.54–1.17). Our meta-analysis comprising real-world observational data concludes that the use of DOAC analogs in morbidly obese patients (bodyweight of > 120 kg or BMI > 40 kg/m2) is non-inferior with regards to efficacy and safety compared to warfarin. This finding helps to resolve the uncertainty associated with the use of DOACs in this cohort. Additionally, it invites for a confirmatory non-inferiority randomized controlled trial testing DOAC vs. Warfarin in this group of patients.